Slide 1: Half-Year Results 2026
Half-Year Results 2026 René Willi, CEO Sven Luginbühl, CFO July 23, 2026 Providing innovative solutions to help people live healthier and more confident lives
Slide 2: Disclaimer and important notes / Safe harbor statement
Disclaimer and important notes / Safe harbor statement under the US Private Securities Litigation Reform Act 1995 This presentation contains forward-looking statements that are based on management’s current assumptions and expectations concerning future developments, including but not limited to, pr
Slide 3: Highlights and Business Review
Highlights and Business Review René Willi, CEO Two-component 5mL cartridge with ColibriTM mixing tip
Slide 4: On track to profitable growth
On track to profitable growth Highlights Group Adjusted Gross profit margin up 120 bps Revenues1 EBITDA margin up 40 bps YoY to 37.8% to 20.3% 214.4 m -1.6% organic3 Within guidance range of Driven by operational -4.9% reported2 around 20% improvements Innovation Continued Industry growth Pivot to H
Slide 5: Business unit revenue and key drivers
Business unit revenue and key drivers Healthcare Segment Consumer & Industrial (C&I) Segment Drug Dental Surgery Industry Beauty Delivery 59.4 16.5 10.3 63.1 65.0 +1.5% -13.8% +31.6% +3.6% -9.2% • Sustained demand for • Continued dual sourcing • Strong growth on • Growth driven by our • Lower volume
Slide 6: Financial Review
Financial Review Sven Luginbühl, CFO Ready-to-go lip gloss packaging with a flocked lip applicator
Slide 7: Continued margin expansion despite lower volumes
Continued margin expansion despite lower volumes CHF millions HY 2026 HY 2025 change • Group revenues declined YoY by 1.6% Revenue 214.4 225.4 -4.9% organically and by 4.9% on a reported basis, Organic revenue growth – – -1.6% reflecting softer underlying demand Gross profit 81.1 82.5 -1.7% particul
Slide 8: Growth in Dental, Surgery & Industry offset by Drug Delivery & Beauty
Growth in Dental, Surgery & Industry offset by Drug Delivery & Beauty -4.9% -1.6% organic 0.9 2.6 2.4 225.4 (2.8) 214.4 (6.8) 221.7 (7.3) 30% C&I 29% 5% Healthcare 8% % Change in organic growth 28% +1.5% +31.6% -13.8% +3.6% -9.2% Revenue Revenue HY 2025 Dental Dental Surgery Sugery Drug Drug Deliver
Slide 9: Improved gross profit margin in Healthcare and C&I
Improved gross profit margin in Healthcare and C&I Healthcare gross profit and margin C&I gross profit and margin 50.0 55.0% 50.0 30.0% 46.8 47.1 54.0% 29.0% 40.0 40.0 53.0% 28.0% 36.1 52.0% 33.9 27.0% 30.0 30.0 51.0% 26.0% 20.0 50.0% 20.0 25.0% HY 25 HY 26 HY 25 HY 26 CHF millions % margin CHF mill
Slide 10: Profitability on track to deliver full-year guidance
Profitability on track to deliver full-year guidance Margin growth sequentially OPEX net of restructuring, impairments for five consecutive half-years and non-ops, CHF 1.4m lower YoY 19.9% 0.7 5.1 20.3% 3.0 44.9 (1.2) 43.5 (5.1) (3.7) Adj. EBITDA Volume Pricing Margin Margin Operating Restructuring,
Slide 11: EBIT – Negatively impacted by one-off restructuring measures and related impairments
EBIT – Negatively impacted by one-off restructuring measures and related impairments 20.0 9.0% 15.0 15.7 6.0% • EBIT decreased by CHF 5.1m to CHF 10.6m (-32.9% YoY) and EBIT as % of revenues was 10.0 10.6 4.9% (-210 bps YoY) 3.0% • Impacted by restructuring and impairments 5.0 measures of CHF 6.4m r
Slide 12: Higher Operating Net Cash Flow driven by lower CAPEX
Higher Operating Net Cash Flow driven by lower CAPEX 9.0 1.9 19.4 (2.8) 15.3 2.5 (5.2) (0.7) (0.4) ONCF EBIT Amortization Depreciation Impairments CAPEX Net Working Others / FX ONCF HY 2025 Capital HY 2026 All amounts in CHF millions and rounded 12
Slide 13: Growth & Efficiency Program: positively impacting profitability
Growth & Efficiency Program: positively impacting profitability On track to achieve planned cost-out targets 2 33 8.4 31 1.6 6.8 Efficiency gains and leaner organizational 22.6 structure achieved through: Operational Excellence: • Automation projects • FTE actions • Procurement savings • Reduction i
Slide 14: Strategy & Outlook
Strategy & Outlook PiccoJectTM: two-step activation autoinjector platform for subcutaneous drug delivery
Slide 15: Strategic Priorities To Ensure Sustainable Growth
Strategic Priorities To Ensure Sustainable Growth 1 Transform medmix into a high-performance organization Healthcare Segment: Dental – Portfolio optimization 6 2 Create the next generation of dental applicators Healthcare Segment: Surgery – C&I segment – 5 3 Becoming a strategic partner Expand margi
Slide 16: Strategic Priorities To Ensure Sustainable Growth
Strategic Priorities To Ensure Sustainable Growth 1 Transform medmix into a high-performance organization Healthcare Segment: Dental – Portfolio optimization 6 2 Create the next generation of dental applicators Healthcare Segment: Surgery – C&I segment – 5 3 Becoming a strategic partner Expand margi
Slide 17: Turning customer needs into innovation: FleXa
Turning customer needs into innovation: FleXaTM Modular Syringe platform for single-component dental materials Customer need: Stronger differentiation, brand visibility, and enhanced user experience Our solution: Co-developed FleXa , a customizable and modular syringe platform Innovation: Drip-reduc
Slide 18: Strategic Priorities To Ensure Sustainable Growth
Strategic Priorities To Ensure Sustainable Growth 1 Transform medmix into a high-performance organization Healthcare Segment: Dental – Portfolio optimization 6 2 Create the next generation of dental applicators Healthcare Segment: Surgery – C&I segment – 5 3 Becoming a strategic partner Expand margi
Slide 19: Strategic Priorities To Ensure Sustainable Growth
Strategic Priorities To Ensure Sustainable Growth 1 Transform medmix into a high-performance organization Healthcare Segment: Dental – Portfolio optimization 6 2 Create the next generation of dental applicators Healthcare Segment: Surgery – C&I segment – 5 3 Becoming a strategic partner Expand margi
Slide 20: Building momentum across Drug Delivery projects pipeline
Building momentum across Drug Delivery projects pipeline Drug Therapy Platform 2026 2027 2028 2029 2030 2031 Generic Andrology PiccoJectTM Biosimilar Growth Disorder Custom Bone Metabolism, Biosimilar D-FlexTM Rheumatology, Obesity Originator Hypothyroidism D-FlexTM Originator Rheumatoid Arthritis P
Slide 21: Strategic Priorities To Ensure Sustainable Growth
Strategic Priorities To Ensure Sustainable Growth 1 Transform medmix into a high-performance organization Healthcare Segment: Dental – Portfolio optimization 6 2 Create the next generation of dental applicators Healthcare Segment: Surgery – C&I segment – 5 3 Becoming a strategic partner Expand margi
Slide 22: Beauty Strategic Priorities for Return-To-Growth
Beauty Strategic Priorities for Return-To-Growth Return-To-Growth 1 2 Cost Containment Program 3 Turnaround Project Commercial Program • Return-to-Growth program • Cost Containment Program • Transformation program launched launched launched with consultants • Focused on delivering immediate • Focuse
Slide 23: Strategic Priorities To Ensure Sustainable Growth
Strategic Priorities To Ensure Sustainable Growth 1 Transform medmix into a high-performance organization Healthcare Segment: Dental – Portfolio optimization 6 2 Create the next generation of dental applicators Healthcare Segment: Surgery – C&I segment – 5 3 Becoming a strategic partner Expand margi
Slide 24: Leveraging expertise to innovate: Industry 400ml 5:1 cartridge
Leveraging expertise to innovate: Industry 400ml 5:1 cartridge E-mobility battery pack manufacturing for a high-end European OEM Customer need: Need for a cartridge with an out of standard ratio to help automotive manufacturer solve an urgent application problem Our solution: Co-developed a tailored
Slide 25: Strategic Priorities To Ensure Sustainable Growth
Strategic Priorities To Ensure Sustainable Growth 1 Transform medmix into a high-performance organization Healthcare Segment: Dental – Portfolio optimization 6 2 Create the next generation of dental applicators Healthcare Segment: Surgery – C&I segment – 5 3 Becoming a strategic partner Expand margi
Slide 26: Outlook
Outlook 2026 guidance • Flat to low single digit organic revenue growth • Adjusted EBITDA margin of around 20% Mid-term guidance (3 years) • Revenue CAGR above 4% (unchanged) • Adjusted EBITDA margin above 21% (unchanged) K system: reliable storage, mixing and delivery of high-value, two-component b
Slide 27: Key Takeaways
Key Takeaways Advancing Healthcare-focused portfolio 01 Strategy transformation to drive profitable growth Margin expansion driven by operational 02 Performance excellence and cost savings despite softer demand High-performance culture fueled by 03 Culture accountability, empowerment and faster deci
Slide 28: Q&A
Q&A René Willi, CEO Sven Luginbühl, CFO
Slide 29: Your Investor Relations contact
Your Investor Relations contact Sven Luginbühl Chief Financial Officer Phone: +41 79 823 05 92 E-mail: investorrelations@medmix.com medmix Group AG Neuhofstrasse 20 6340 Baar Switzerland